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Summary.-A reduction in tumour yield was apparent when progesterone adminis-
tration was begun 25 days before feeding 7,12-dimethylbenz(a)anthracene (DMBA).
This effect was most obvious when the duration of hormone administration was
brief. Continuation of progesterone for some time after feeding DMBA caused a
progressive diminution of the inhibitory effect, and 135 days of continuous hormone
treatment entirely abolished the effects of 25 days pretreatment with the hormone.
In contrast, when progesterone injections were begun 2 days after feeding DMBA,
there was a trend towards enhancement of tumour yield. Continuous hormone
administration appeared more effective than shorter treatment regimens.
PREVIOU-S investigations have shown
that exogenous progesterone, while not
carcinogenic per se, significantly enhances
7,12-dimethylbenz(a)anthracene (DMBA)
mammary tumorigenesis in entire rats.
This effect was shown when continuous
hormone injections were begun 2 days
before or 15 days after carcinogen adminis-
tration or after the first tumour had
appeared (Jabara, 1967; Jabara and
Harcourt, 1970), or when daily injections
of progesterone were given for only 30
days, beginning 15 days after feeding
DMBA (Huggins, Moon and Morii, 1962).
In contrast, Welsch, Clemens and Meites
(1968) reported that prolonged (25 days)
daily treatment with progesterone before
administering DMBA significantly
inhibited mammary tumorigenesis, even
although hormone injections were
continued for 15 days after carci-
nogen administration.
The present experiments were designed
to determine the effect of variations in
the time at which hormone administration
was begun, and in the duration ofhormone
treatment, on the enhancing effect of
5
progesterone on DMBA mammary tumori-
genesis.
MATERIALS AND METHODS
One hundred and forty-eight non-inbred
Sprague-Dawley virgin female rats were
divided randomly into 8 progesterone-treated
groups of 16 rats each and one control
group of 20 animals (Table I). They were
housed 5 rats/cage and fed commercial
pellets and water ad libitum. At 50 days
of age each rat in all 9 groups was fed by
gastric intubation with a single dose of
30 mg of DMBA (Eastman Organic Chemi-
cals, U.S.A.) dissolved in 2 ml of corn oil.
In addition, each animal in Groups 2-9
received subcutaneous injections of 3 mg
of progesterone (Sigma Chemical Co., U.S.A.)
dissolved in 0-1 ml of corn oil/day 3 times a
week. In Groups 2-5, progesterone injec-
tions were begun 25 days before DMBA
administration (i.e. on their 25th day of
age) (DMBA + P -25) and were continued
for 18, 36, 54 and 160 days for Groups 2-5
respectively. In Groups 6-9, hormone injec-
tions were begun 2 days after feeding DMBAANNE G. JABARA, P. H. TOYNE AND ALISON G. HARCOURT
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(i.e. on their 52nd day of age) (DMBA + P
+ 2) and -were continued for 9, 18, 27 and
133 days for Groups 6-9 respectively. Alloca-
tion of the 9 groups to the possible factor
combinations is summarized as follows:
Time of
beginning
progesterone
treatment
DMBA only
DMBA +P-23
DMBA+P+2
No
treatmenit,
with
progesterone
1
Duration of
progesterone
treatment
Short Continuous
. 2, 3, 4 .)
(, 7, 8 9
Beginning 4 weeks after DMBA adminis-
tration, all rats wvere palpated weekly and
any mammary tumours recorded, measured
and graphed as described previously (Jabara,
1967). Portions of each mammary tumour
were removed at autopsy, fixed in
10% buffered formalin and 5 ,um paraffin
sections were stained with haematoxylin and
eosin.
The statistical analysis of the results was
based on the following 7 parameters of
tumour yield: tumour incidence (the number
of rats developing a tumour, of those which
survived longer than 28 days after DMBA
administration), latent period (the time
interval between feeding DMBA and the
appearance of the first tumour), average
number of active tumour centres per rat
(the number of tumours per rat which were
palpable for at least 5 weeks and/or wvere
visible macroscopically at autopsy averaged
over all rats in a group, including those
rats which did not develop a neoplasm),
tumour growth behaviour and size, tumour
locations and types of neoplasm developed
(Jabara, 1967).
The first 2 of these parameters, tumour
incidence and latent period, together with
the date of death of rats which died from
other causes before any tumour had deve-
loped, determined the shape of the actuarial
survival curve in which the proportion of
rats still alive and without any tumours
was plotted against the time lapsed since
administration of DMBA (Pike and Roe,
1963). By using the curve derived from
the results for the 147 rats which survived
more than 28 days after feeding DMBA,
the number of rats in each group expected
to develop a tumour under the null hypo-
thesis of no difference between groups can
be estimated (Roe et al., 1970).
The remaining 5 parameters were not
suitable for analysis by the actuarial method,
and standard statistical techniques were
therefore used in their analysis. The average
numbers of active tumour centres developed
per rat were compared by an analysis of
variance, the data first being transformed
using a square root transformation. An
arcsin transformation was used for compari-
sons of tumour size between the several
groups. In all other eases, the X2-test was
used for comparisons between groups.
The overall effect of the starting time for
progesterone treatment was assessed by
comparing Groups 2-5 and Groups 6-9
with each other and with Group 1. The
effect of the duration of progesterone treat-
ment was examined within the DMBA + P
-25 groups by comparing Groups 2, 3, 4
and 5, and within the DMBA + P + 2
groups by comparing Groups 6, 7, 8 and 9.
The possibility ofinteraction betweenstarting
time and duration of hormone treatment
was examined by comparing each of Groups
2-4, Group 5, Groups 6-8 and Group 9 with
the control Group 1.
RESULTS
No mammary tumour was observed
to develop during the first 4 weeks follow-
ing carcinogen administration. Twenty-
three rats in the 8 progesterone-treated
groups died or were killed between the
4th week and the end of the experiment
(135 days after feeding DMBA) (Table I).
The average survival times for these rats
were 110, 120, 94, 96-5, 76, 99, 75 and 88
days in Groups 2-9 respectively. Twelve
of these rats had developed tumours
before death, and 11 were tumour free.
All rats in the control group which were
alive 28 days after receiving DMBA
survived for the remainder of the experi-
ment.
Tumour incidence
The observed tumour incidence in
each group was compared with the cor-
responding expected incidence under theANNE G. JABARA, P. H. TOYNE AND ALISON G. HARCOURT
TABLE II. Observed and (Actuarially) Expected Incidence of Tumours
Time of beginning
progesterone
treatment
DAIBA only O
DMBA+P-25
DMBA+P+ 2
Duration of progesterone treatmeint
No treatment with ,-
progesteronie Short Continuous
13
12-76
1 04 - -
E
R
0
E
R
0
E
R
6 7 8
- . 12-49 12-67 10-30
- 049 0*56 0*79
11 11 9
-6-39 9'80 9.50
1*76 1*14 0*97
11
9 *26
1 *21
13
5-82
2 -28
0 = observed incidence; E - expected incidence; R = ielative incidence rate (O/E).
null hypothesis of no difference between
groups. The expected incidences were
calculated using the actuarial survival
curve following the method described
by Roe et al. (1970). The observed (0)
and expected (E) incidences, and the
relative incidence rates (R- O/E) are
shown in Table II. The X2 value for
Table II was 19a1, with 8 degrees of
freedom (P < 0 02). Using the actuarial
method, the estimated probability that a
rat would develop at least one tumour
during the experimental period has been
calculated for each group (Table I).
The relative incidence rates indicated
that pretreatment with progesterone in-
hibited tumorigenesis, except in the group
(5) in which progesterone treatment was
continued for the duration of the experi-
ment (Table II). Beginning hormone ad-
ministration 2 days after feeding DMBA
enhanced tumorigenesis in 3 of the 4
groups so treated (Group 8 being the
exception); the effect was again particu-
larly marked in the group (9) in which
progesterone was given throughout the
whole experiment (Table II).
Of the 6 groups of rats which received
progesterone for only short periods, there
appeared to be a progressive increase in
tumorigenesis with increasing duration
of hormone treatment in the 3 hormone
pretreated groups (2, 3 and 4), but
tumorigenesis did not show a progressive
increase with increasing length of hor-
mone treatment in Groups 6, 7 and 8,
in which progesterone injections were
begun 2 days after DMBA administration
(Table II).
Active tumour centres
The analysis of the results observed
for this parameter was based on the
figures recorded for the 124 rats which
survived for the whole experimental
period. The average number of active
tumour centres per rat (ATCs) was based
on all rats in a group, including those
which did not develop a neoplasm.
A significantly higher average number
of ATCs arose in Groups 6-9 compared
with the average number in Groups 2-5
(Table I and IV). However, when the
average number of ATCs in Groups 6-9
and in Groups 2-5 were each compared
separately with the controls, the differ-
ences were not significant (Table I and
IV).
The average numbers ofATCs obtained
in Groups 2, 3 and 4 did not differ signifi-
cantly from each other, nor was the
overall average for these 3 groups
significantly lower than that observed in
Group 5. However, the pooled average
for Groups 2-4 was significantly lower
than the pooled average for Groups 6-8
and that observed in the controls (Table
I and IV). There was no significant
difference between the average numbers
of ATCs per rat observed in Groups 6,
7 and 8, nor did the pooled average for
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TABLE III. Tumour Growth Behaviour, Locations and Histological Tumour Types
Induced
Group no.
1 2 3 4 5 6 7 8
9
Growth behaviour of tumouirs:
No. classified CG
No. classified S
No. classified R
No. unclassified*
No. of measurable tumours
No. of rats bearing measurable tumours
Locations of tumours:
No. in anterior 3 pairs
No. in posterior 3 pairs
Histological tumour types:
No. classified carcinoma
No. classified (fibro)adenoma
No. unclassifiedt
3
9
8
12
3
3
1
0
4
3
3
5
7
1
6
6
5
I
10
2
3
3
3
8
13
6
a
17
10
7
5
2
11
9
7
3
7
10
6 5
3
5
6
1
3
6
5
23
7
14
14
6
22 9 15 12 26 20 18 12 30
10 1 4 4 6 5 3 3 19
28 7
3 1
1 2
15
0
4
12
0
4
22
5
22
2
2
17
1
3
9
I
33
6
10
* Growth behaviour could not be classified as either no measuremenits or insufficient measuirements of
ttimours were obtained before death of the host.
t Tumours could not be classified (lue to complete regression before autopsy.
CG = continuous growth
S = static growth
R = regressing
TABLE IV. Summary ofStatistical Analyses
Active tumouir
centres
NS
NS
P_ 0 003
P= 0-027
P= 0-022
NS
P _0-*005
P= 0 026
NS
NS
1- 0.011
Tumour growth
behaviour
NS
P= 0-048
NS
NS
NS
NS
P= 0-041
P 0-031
NS
P=z 0 019
NS
Tumour
size
P < 0001
P 0003
NS
NS
P= 0-026
P= 0-006
NS
P 0033
P < 0.001
P= 0 003
P = 0-013
Tumour
locations
NS
NS
NS
NS
NS
NS
P = 0-027
NS
NS
NS
NS
For histological tumour types develope(l all of the above comparisons were found to be not significant
(NS).
these 3 groups differ significantly from
that for the controls. Likewise, the
average number of ATCs per rat in
Group 5 did not differ significantly from
that observed in the controls. However,
all 3 groups, i.e. the controls, Group 5
and the pooled group containing the
original Groups 6-8, gave values which
were significantly lower than the average
number of ATCs per rat in Group 9
(Table IV).
Tumour growth behaviour and tumour size
The results were based on all observed
tumours, including those which developed
in rats which died or were killed before
the end of the experiment. With the
exception of Group 2, in which no regres-
sing tumours were observed, 3 main
types of tumour growth behaviour (TGB)
(Jabara, 1967) occurred in animals of all
groups (Table III).
The TGB of classifiable neoplasms in
all progesterone-treated groups (2-9) was
significantly different from that in the
controls (P 0 027), and was due to a
relatively high number of regressing
tumours in Group 1 (Table III).
Investigations into the effect of the
duration of progesterone administration
on TGB showed that the TGB in Groups
Group
comparisons
2-
2-
2-
6-
1 v 2-5
1 v 6-9
-5 V 6-9
-4 v 6-8
4v6 9
-4 v .5
-8 V (3
1 v2-4
1 v 1 v 6-8
I v 9)-
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6-8, receiving progesterone for relatively
short periods, was significantly different
from that in Group 9 (Table III and
IV). This difference was ascribed to a
relative excess of continuously growing
neoplasms and a relative shortage of
regressing tumours in Groups 6-8 com-
pared with those in Group 9 (Table III).
Groups 6-8 and Groups 6-9 also differed
significantly from the controls with respect
to this parameter (Table III and IV),
again due to a relative excess of con-
tinuously growing tumours in the first
3 groups and to a relative excess of
regressing neoplasms in the controls
(Group 1). While the TGB of Groups
2-4 was not significantly different from
that in Group 5, it differed significantly
from that in the controls (Table III and
IV). This difference was based on rela-
tively small numbers of classifiable neo-
plasms (32 in Groups 2-4 and 20 in
Group 1), but again it appeared to be
due to a relative excess of regressing
growths in Group 1.
No other significant effects on TGB
were found (Table IV).
A highly significant difference was
observed between the number of tumours
which reached a measurable size (1cm
or more in longest diameter) of all those
that developed in the control group (1)
compared with those arising in the 8
progesterone-treated groups (P < 0.01)
(Table III and IV). This difference was
ascribed to the small proportion of
measurable tumours developed in Group
1. Within the 8 groups treated with
various progesterone regimens, Group 5
was the only one which showed a signifi-
cantly higher incidence of measurable
tumours compared with that in Groups
2-4 and 6-8 combined (P 0 010) and
that in Group 9; it was also significantly
higher than that in Group 1 (Table IV).
Location
In all 9 groups,
equally on both sides.
growths in all groups
neoplasms arose
The majority of
developed in the
anterior 3 pairs of glands, and less often
in the 4th, 5th and 6th pairs (Table III).
However, comparisons between the num-
bers of tumours arising in the first 3
pairs of mammae and the numbers
developing in the last 3 pairs revealed
that while Group 9 was not significantly
different from the controls, this group
differed significantly not only from groups
6-8 (Table IV), but from all the other
progesterone-treated groups (P 0 020).
This difference was due to a relative
excess of neoplasms arising in the 3
pairs of abdominal glands in Group 9
(Table III).
Types of tumours
The classifiable tumours arising in
rats of all groups consisted of both benign
and malignant growths (Jabara, 1967),
except in Groups 3 and 4 where only
carcinomata arose (Table III). Proges-
terone appeared not to influence either
the macroscopic or microscopic appear-
ances of the developing tumours, regard-
less of when injections were begun or for
how long they were continued. Com-
parisons of the proportions of benign to
malignant tumours developed per group
showed that the 2 groups receiving pro-
gesterone continuously (5 and 9) deve-
loped significantly more benign tumours
than the 6 groups treated with the
hormone for only short periods (P 0.031)
(Table III). However, these 2 groups
did not differ significantly from each
other, or from Group 1, in this regard.
DISCUSSION
Results obtained in the DMBA+P-25
groups in the present series confirmed the
findings of Welsch et al. (1968) that
prolonged pretreatment with progesterone
before feeding DMBA markedly reduced
the incidence of mammary tumours if
progesterone administration is continued
only for a short time after carcinogen
administration. However, the data have
also shown that an even greater inhibition
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of mammary tumorigenesis was obtained
bystopping hormone administration before
feeding DMBA, and further that the
longer progesterone was administered
after feeding DMBA, the progressively
less obvious became the inhibitory effect
of hormone pretreatment on tumori-
genesis; 135 days of continuous pro-
gesterone administration after DMBA
abolished the inhibitory effect of 25
days of hormone pretreatment.
Hormone pretreatment, as shown in
the series of Welsch and his colleagues,
resulted in a significant reduction in
the number of active tumour centres per
rat in the 3 groups (2-4) receiving only
short post-treatment with the hormone
compared with those in the controls.
However, the inhibitory effect of 25 days
of hormone pretreatment was abolished
by continuing progesterone administra-
tion for 135 days after feeding DMBA.
Tumours were not weighed in the present
series, but the fact that tumour size,
compared with that in the controls, was
significantly increased in all progesterone-
treated groups, regardless of the time of
its administration or its duration, strongly
suggests that the total weight of tumours
per rat was probably also increased,
contrasting with the significant reduction
in tumour weight observed by Welscb
et al. (1968).
With one exception, both short and
continuous post-treatment with proges-
terone (DMBA + P + 2) was found to
enhance the mammary tumour incidence
compared with the controls, continuous
administration being much more effective
in this regard than shorter regimens.
Group 8 was exceptional in that its
tumour incidence approximated that
observed in the controls. The reason for
lack of tumour enhancement in this
group is inexplicable. In contrast to the
pretreated groups, tumorigenesis did not
show a progressive increase with increasing
duration of hormone treatment in the
short post-treated groups (6-8). One
explanation for this observation could
be due to the shorter (9-day) time intervals
between stopping the different hormone
regimens in Groups 6-8, compared with
18-day intervals in the pretreated Groups
2-4, the longer time interval in the
latter groups probably allowing differ-
ences between treatment regimens to
become more obvious.
The previously reported significant
enhancement of active tumour centres
per rat following continuous post-treat-
ment with progesterone (Jabara, 1967;
Jabara and Harcourt, 1970) was con-
firmed in Group 9 of the present series.
However, unlike Huggins et al. (1962),
who reported a significant enhancement
of ATCs per rat following short (30 days)
hormone post-DMBA treatment, only a
trend towards enhancement of ATCs was
observed in Group 6 of the present
series, whereas in the other 2 groups also
receiving short post-treatment with pro-
gesterone there was a non-significant
trend towards a reduction in ATCs
developed per rat. The explanation for
the differences between the present series
and that of Huggins and colleagues may
lie in the length of the experimental
period. The present experiment was ter-
minated 135 days after feeding DMBA
compared with 180 days in that of
Huggins et al. (1962). In rats fed only
DMBA, the majority of benign tumours
tends to arise several weeks or months
later than do malignant ones (Daniel and
Prichard, 1964; Jabara, 1967). In con-
trast, administration of progesterone in
addition to DMBA tends to hasten the
appearance ofbenign, as well as malignant,
growths (Jabara, 1967). Hence, the
longer the experimental period, the more
apparent become the differences in the
various parameters of tumour yield
between groups of animals treated with
DMBA alone and those treated with
progesterone as well. The relatively short
experimental period used in the present
series probably also explains the non-
significant increase in benign tumours
observed in the 2 groups (5 and 9) which
received progesterone continuously com-
pared with the number arising in the7 ANNE G. JABARA, P. H. TOYNE ANI) ALISON G. HARCOURT
controls. However, the experimental
period was. long enough to demonstilate
that continuous hormone administration
resulted in the appearance of significantly
more benign growths than did shorter
hormone regimens. In view of the fact
that continuous progesterone administra-
tion in previous series (Jabara, 1967;
Jabara and Harcourt, 1970) and in
Group 5 (DMBA + P - 25 to + 135)
of the present experiments has not been
found to influence significantly the loca-
tions of neoplasms, 'it is suggested that
the significant increase in the number of
tumours arising in the abdominal pairs
of mammary glands in Group 9 (DMBA
+ P + 2 to + 135) probably can be
ascribed to a random effect.
Continuous post-treatment with pro-
gesterone in previous investigations did
not result in any demonstrable modifica-
tion of tumour growth behaviour (Jabara,
1967; Jabara and Harcourt, 1970), al-
though Huggins et al. (1962) reported an
increase in tumour growth rate in rats
injected with progesterone from +15 to
4-45 days after carcinogen administration.
The findings in the present series confirm
those of Huggins and' his colleagues and
further show that the presence of pro-
gesterone, regardless of the time of
beginning its administration or its dura-
tion, appears to promote tumour growth
as assessed by both tumour growth
behaviour and tumour size. The signifi-
cantly higher incidence of measurable
tumours- in- Grou'p 5 (DMBA + P - 25
to + 135) c'ompared with those in the
other 7 progesterone regimens, probably
reflects the long period '(160 days) of
hormone treatment in this group com-
pared with 133 days in Group 9 and
between 9 and 54 days duration in the
other 6 hormone-treated groups.
The observation that neither short
nor continuous post-treatment with pro-
gesterone (Groups 6-9)'significantly modi-
fied the types of tumours developed
confirms the findings in previous investi-
gations (Huggins et al., 1962; Jabara and
Harcourt, 1970).
It is concluded that when progesterone
administration 'was begun 2 days after
feeding DMBA, regardless of its duration,
it resulted in a trend towards an enhance-
ment of several'' parameters of tumour
yield, TGB and tumour size both being
significantly enhanced. Continuous post-
treatment with the hormone appeared
much more. effective than shorter treat-
ment regimens. However, pretreatment
with progesterone, particularly when
begun early and administered for only a
short period, decreased DMBA tumori-
genesis. The mechanism whereby long
progesterone pretreatment produces this
effect is not yet known. Prolonged treat-
ment with progesterone causes marked
lobular-alveolar development of the' rat
mammary gland and Welsch et al. (1968)
suggested that this enhanced mammary
development close to the time of adminis-
tering DMBA rendered the gland rela-
tively refractory to carcinogen action.
However, investigations have shown both
the level of DNA synthesis in mammary
epithelial cells and the extent ofmammary
gland development close to the time of
carcinogen administration to be similar in
2 groups 'of rats given progesterone,
beginning at either 25 or 2 days before
feeding DMBA (Jabara, Toyne and Fisher,
1972); continuous progesterone adminis-
tration when begun 2 days before feeding
the carcinogen significantly enhances
DMBA tumorigenesis (Jabara, 1967;
Jabara and Harcourt, 1970). These
observations therefore fail to confirm' the
suggestion advanced by Welsch and his
colleagues. Dao- (1971), on the other
hand, has 'suggested that the presence
of excessive amounts of steroid hormone
at receptor sites in mammary epithelial
cells may block interaction between
DMBA and these sites and hence inhitAt
the induction of mammary tumours.
In view of the fact that the 'rat rapidly
metabolizes progesterone (Davie's and
Ryan, 1972), this hypothesis fails to
explain why the greatest' depression in
ov'erall tumour yield occurred in the pre-
treated group (2) in which progesterone
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administration was stopped 7 days before
feeding DMBA. It appears that long
progesterone pretreatment combined with
DMBA administration could serve as a
useful model for tumour initiation studies.
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